COGZF (Cogstate) Interest Expense : $-0.05 Mil (TTM As of Jun. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Cogstate Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cogstate's interest expense for the six months ended in Jun. 2024 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.05 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cogstate's Operating Income for the six months ended in Jun. 2024 was $ 6.26 Mil. Cogstate's Interest Expense for the six months ended in Jun. 2024 was $ -0.02 Mil. Cogstate's Interest Coverage for the quarter that ended in Jun. 2024 was 368.29. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cogstate Interest Expense Historical Data

The historical data trend for Cogstate's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogstate Interest Expense Chart

Cogstate Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Interest Expense

Get a 7-Day Free Trial

-0.15

-0.09

-0.07

-0.05

Cogstate Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Interest Expense	Get a 7-Day Free Trial															-0.05	-0.04	-0.03	-0.03	-0.02

Cogstate Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.05 Mil.

Cogstate (OTCPK:COGZF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cogstate's Interest Expense for the six months ended in Jun. 2024 was $-0.02 Mil. Its Operating Income for the six months ended in Jun. 2024 was $6.26 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was $0.46 Mil.

Cogstate's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2024 )	/	Interest Expense (Q: Jun. 2024 )
	=	-1	*	6.261	/	-0.017
	=	368.29

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Cogstate Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Cogstate Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cogstate Ltd (OTCPK:COGZF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CGS:Australia

Address

161 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cogstate.com

Cogstate Ltd is a cognitive science company. The principal activity of the group is Creation, validation and commercialisation of digital brain health assessments; and Design and provision of quality assurance services in clinical trials, focused on the administration, scoring and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.